Braak H, Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59.

Hyman BT, Phelps CH, Beach TG et al. National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 2012; 8: 1-13.

Leuzy A., Savitcheva I., Chiotis K., Lilja J., Andersen P., Bogdanovic N. Jelic V., Nordberg A. Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis. Eur J. Nucl Med and Mol Imaging 2019; 46:1276–1286

McKhann G, Drachman D, Folstein M et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939-44.

McKhann G, Knopman D, Chertkow H et al. The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement 2011; 7: 263-9.

Mirra SS, Heyman A, McKeel D et al. The Consortium to Establish a Registry for Alzheimer’s Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer’s disease. Neurology 1991; 41: 479-86.

Rowe CC, Ng S, Ackermann U, Gong SJ, Pike K, Savage G et al. Imaging b-amyloid burden in aging and dementia. Neurology 2007, 68: 1718-25.

Thurfjell L., Lilja J., Lundqvist R., Buckley C., Smith A., Vandenberghe R., Sherwin P. Automated Quantification of 18F-Flutemetamol PET Activity for Categorizing Scans as Negative or Positive for Brain Amyloid: Concordance with Visual Image Reads. J Nucl Med. 2014; 55:1–6

Vandenberghe R, Van Laere K, Ivaniou A et al.18F-Flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial. Ann Neurol 2010; 68: 319-29.

Vizamyl Summary of Product Characteristics